Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application

Applied Microbiology and Biotechnology

Volumn 100, Issue 20, 2016, Pages 8693-8699

  Ou, Bingming ^a   Yang, Ying ^a   Tham, Wai Liang ^a,b   Chen, Lin ^a,c   Guo, Jitao ^d   Zhu, Guoqiang ^a  

^a YANGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c JIANGSU AGRI ANIMAL HUSBANDRY VOCATIONAL COLLEGE   (China)

^d INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Chromosome; Clinical application; Cryptic plasmids; Genetic modification; Nissle 1917

Indexed keywords

CHROMOSOMES; ESCHERICHIA COLI; VACCINES;

CLINICAL APPLICATION; CRYPTIC PLASMIDS; GENETIC MODIFICATIONS; NISSLE 1917; OUTER MEMBRANE VESICLES; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PLASMID; VACCINE DEVELOPMENT;

GENETIC ENGINEERING;

BACTERIAL VACCINE; PROBIOTIC AGENT; RECOMBINANT VACCINE;

CHROMOSOME; COLIFORM BACTERIUM; DRUG; DRUG DEVELOPMENT; GENE TRANSFER; PLASMID; PROBIOTICS; VACCINE;

BACTERIAL CHROMOSOME; BACTERIAL OUTER MEMBRANE; DNA MODIFICATION; ESCHERICHIA COLI; GENETIC ENGINEERING; NONHUMAN; RECOMBINANT PLASMID; REVIEW; GENETICS; IMMUNOLOGY; METABOLISM;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI NISSLE 1917;

ESCHERICHIA COLI; GENETIC ENGINEERING; PROBIOTICS; VACCINES, SYNTHETIC;

EID: 84988378020     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-016-7829-5     Document Type: Review

References (60)

1. Amiri-Jami M, Abdelhamid AG, Hazaa M, Kakuda Y, Griffths MW (2015) Recombinant production of omega-3 fatty acids by probiotic Escherichia coli nissle 1917. FEMS Microbiol Lett 362(20):fnv166. doi:10.1093/femsle/fnv166
2. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H (2006) Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2(1). doi:10.1038/msb4100050
3. Bai L, Tang S, Wen Y, Yang Q, Sun Y, Hu S, Ding X, Xia L (2015) Construction of invasive engineered strain targeted for cancer therapy using transposon. Sci China Life Sci 2:011
4. Baxter D (2007) Active and passive immunity, vaccine types, excipients and licensing. Occupational Med 57(8):552–556. doi:10.1093/occmed/kqm110
5. Benz I, Schmidt MA (2011) Structures and functions of autotransporter proteins in microbial pathogens. Int J Med Microbiol 301(6):461–468. doi:10.1016/j.ijmm.2011.03.003
6. Blum-Oehler G, Oswald S, Eiteljörge K, Sonnenborn U, Schulze J, Kruis W, Hacker J (2003) Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol 154(1):59–66. doi:10.1016/S0923-2508(02)00007-4
7. Brader P, Stritzker J, Riedl CC, Zanzonico P, Cai S, Burnazi EM, Ghani ER, Hricak H, Szalay AA, Fong Y (2008) Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin Cancer Res 14(8):2295–2302. doi:10.1158/1078-0432.CCR-07-4254
8. Buddenborg vvC (2005) Orale Immunisierung mit rekombinanten Escherichia coli NISSLE 1917: Charakterisierung der humoralen Immunantwort gegen Oberflächenexprimierte heterologe Antigene aus Borrelia burgdorferi und Listeria monocytogenes. Dissertation, Westfälische Wilhelms-Universität Münster
9. Buddenborg C, Daudel D, Liebrecht S, Greune L, Humberg V, Schmidt MA (2008) Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier. Int J Med Microbiol 298(1):105–114. doi:10.1016/j.ijmm.2007.08.008
10. Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrede JP (2010) Escherichia coli Induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A 107(25):11537–11542. doi:10.1073/pnas.1001261107
11. Danino T, Prindle A, Kwong GA, Skalak M, Li H, Allen K, Hasty J, Bhatia SN (2015) Programmable probiotics for detection of cancer in urine. Sci Transl Med 7(289):289ra84–289ra84. doi:10.1126/scitranslmed.aaa3519
12. Datsenko KA, Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97(12):6640–6645. doi:10.1073/pnas.120163297
13. Datz M, Janetzki-Mittmann C, Franke S, Gunzer F, Schmidt H, Karch H (1996) Analysis of the enterohemorrhagic Escherichia coli O157 DNA region containing lambdoid phage gene p and Shiga-like toxin structural genes. Appl Environ Microbiol 62(3):791–797
14. Duan F, March JC (2008) Interrupting Vibrio cholerae infection of human epithelial cells with engineered commensal bacterial signaling. Biotechnol Bioeng 101(1):128–134. doi:10.1002/bit.21897
15. Duan F, March JC (2010) Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc Natl Acad Sci U S A 107(25):11260–11264. doi:10.1073/pnas.1001294107
16. Duan F, Curtis KL, March JC (2008) Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. Appl Environ Microbiol 74(23):7437–7438. doi:10.1128/AEM.01019-08
17. Feldgarden M, Golden S, Wilson H, Riley MA (1995) Can phage defence maintain colicin plasmids in Escherichia coli. Microbiology 141(11):2977–2984. doi:10.1099/13500872-141-11-2977
18. Fernández LA, Sola I, Enjuanes L, De Lorenzo V (2000) Specific secretion of active single-chain Fv antibodies into the supernatants of Escherichia colicultures by use of the hemolysin system. Appl Environ Microbiol 66(11):5024–5029. doi:10.1128/AEM.66.11.5024-5029.2000
19. Gardlik R, Palffy R, Celec P (2012) Recombinant probiotic therapy in experimental colitis in mice. Folia Biol (Praha) 58(6):238–245
20. Gronbach K, Eberle U, Muller M, Olschlager TA, Dobrindt U, Leithauser F, Niess JH, Doring G, Reimann J, Autenrieth IB, Frick JS (2010) Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun 78(7):3036–3046. doi:10.1128/iai.00218-10
21. Guenther K, Straube E, Pfister W, Guenther A, Huebler A (2010) Sever sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr Infect Dis J 29(2):188–189. doi:10.1097/INF.0b013e3181c36eb9
22. Hacker J, Carniel E (2001) Ecological fitness, genomic islands and bacterial pathogenicity. EMBO Rep 2(5):376–381. doi:10.1093/embo-reports/kve097
23. Inic-Kanada A, Stojanovic M, Schlacher S, Stein E, Belij-Rammerstorfer S, Marinkovic E, Lukic I, Montanaro J, Schuerer N, Bintner N (2015) Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers. PLoS One 10(12):e0144380. doi:10.1371/journal.pone.0144380
24. Konieczny MP, Suhr M, Noll A, Autenrieth IB, Alexander Schmidt M (2000) Cell surface presentation of recombinant (poly-) peptides including functional T-cell epitopes by the AIDA autotransporter system. FEMS Immunol Med Mic 27(4):321–332. doi:10.1111/j.1574-695X.2000.tb01446.x
25. Kudela P, Koller VJ, Mayr UB, Nepp J, Lubitz W, Barisani-Asenbauer T (2011) Bacterial ghosts as antigen and drug delivery system for ocular surface diseases: effective internalization of bacterial ghosts by human conjunctival epithelial cells. J Biotechnol 153(3):167–175. doi:10.1016/j.jbiotec.2011.03.022
26. Lehouritis P, Stanton M, McCarthy FO, Jeavons M, Tangney M (2015) Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria. J Control Release 222:9–17. doi:10.1016/j.jconrel.2015.11.030
27. Li C, Zhu Y, Benz I, Schmidt MA, Chen W, Mulchandani A, Qiao C (2008) Presentation of functional organophosphorus hydrolase fusions on the surface of Escherichia coli by the AIDA-I autotransporter pathway. Biotechnol Bioeng 99(2):485–490. doi:10.1002/bit.21548
28. Magistrelli C, Colombo E, Tognoni A, Grandi G (1992) Transfection of E. coli with lambda DNA by electroporation. Microbiologica 15(4):397–398
29. Majander K, Anton L, Antikainen J, Lång H, Brummer M, Korhonen TK, Westerlund-Wikström B (2005) Extracellular secretion of polypeptides using a modified Escherichia coli flagellar secretion apparatus. Nat Biotechnol 23(4):475–481. doi:10.1038/nbt1077
30. Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W (2005) Bacterial ghosts as antigen delivery vehicles. Adv Drug Deliver Rev 57(9):1381–1391. doi:10.1016/j.addr.2005.01.027
31. McCarthy AJ, Martin P, Cloup E, Stabler RA, Oswald E, Taylor PW (2015) The Genotoxin Colibactin Is a Determinant of Virulence in Escherichia coli K1 Experimental Neonatal Systemic Infection. Infect Immun 83(9):3704–3711. doi:10.1128/iai.00716-15
32. Montanaro J, Inic-Kanada A, Ladurner A, Stein E, Belij S, Bintner N, Schlacher S, Schuerer N, Mayr UB, Lubitz W (2015) Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface. Drug Des Devel Ther 9:3741. doi:10.2147/DDDT.S84370
33. Monteiro C, Saxena I, Wang X, Kader A, Bokranz W, Simm R, Nobles D, Chromek M, Brauner A, Brown RM (2009) Characterization of cellulose production in Escherichia coli Nissle 1917 and its biological consequences. Environ Microbiol 11(5):1105–1116. doi:10.1111/j.1462-2920.2008.01840.x
34. Muhammad A, Champeimont J, Mayr UB, Lubitz W, Kudela P (2012) Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev Vaccines 11(1):97–116. doi:10.1586/erv.11.149
35. Niewerth U, Frey A, Voss T, Le Bouguénec C, Baljer G, Franke S, Schmidt MA (2001) The AIDA autotransporter system is associated with F18 and stx2e in Escherichia coli isolates from pigs diagnosed with edema disease and postweaning diarrhea. Clin Diagn Lab Immunol 8(1):143–149. doi:10.1128/CDLI.8.1.143-149.2001
36. Nissle A (1918) Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien. Med Klin 2:29–30
37. Nissle A (1925) Weiteres über Grundlagen und Praxis der Mutaflorbehandlung. DMW-Deutsche Medizinische Wochenschrift 51(44):1809–1813
38. Nougayrede JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E (2006) Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313(5788):848–851. doi:10.1126/science.1127059
39. Olier M, Marcq I, Salvador-Cartier C, Secher T, Dobrindt U, Boury M, Bacquie V, Penary M, Gaultier E, Nougayrede JP, Fioramonti J, Oswald E (2012) Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity. Gut Microbes 3(6):501–509. doi:10.4161/gmic.21737
40. Oswald S (2006) Molekularbiologische Untersuchungen des probiotischen Escherichia coli Stammes DSM 6601 und Entwicklung der stammeigenen Plasmide als Klonierungsvektoren. Dissertation, Julius-Maximilians-Universität Würzburg
41. Paukner S, Stiedl T, Kudela P, Bizik J, Al Laham F, Lubitz W (2006) Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin Drug Deliv 3(1):11–22. doi:10.1517/17425247.3.1.11
42. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, Fekete RA, Kar S, Adhya S, Hamer DH (2005) Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A 102(34):11993–11998. doi:10.1073/pnas.0504881102
43. Remer KA, Bartrow M, Roeger B, Moll H, Sonnenborn U, Oelschlaeger TA (2009) Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88. Int J Med Microbiol 299(7):467–478. doi:10.1016/j.ijmm.2009.03.003
44. Riedel CU, Casey PG, Mulcahy H, O’Gara F, Gahan CG, Hill C (2007) Construction of p16Slux, a novel vector for improved bioluminescent labeling of gram-negative bacteria. Appl Environ Microbiol 73(21):7092–7095. doi:10.1128/AEM.01394-07
45. Rosenthal J (2014) Engineered Outer Membrane Vesicles Derived From Probiotic Escherichia coli Nissle 1917 As Recobinant Subunit Antigen Carreirs For The Development Of Pathogen-Mimetic Vaccines. Dissertation, Cornell University
46. S. O. (1997) Einführung von Virulenz-assoziierten Antigenen in den Escherichia coli-Carrier-Stamm DSM 6601. Dissertation, Julius-Maximilians-Universität Würzburg
47. Sabharwal H, Cichon C, Olschlager TA, Sonnenborn U, Schmidt MA (2016) Interleukin-8, CXCL1, and MicroRNA miR-146a Responses to Probiotic Escherichia coli Nissle 1917 and Enteropathogenic E. coli in Human Intestinal Epithelial T84 and Monocytic THP-1 Cells after Apical or Basolateral Infection. Infect Immun 84(9):2482–2492. doi:10.1128/iai.00402-16
48. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K (2007) Induction of human β-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 75(5):2399–2407. doi:10.1128/IAI.01563-06
49. Seo E-j, Weibel S, Wehkamp J, Oelschlaeger TA (2012) Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. Int J Med Microbiol 302(6):276–287. doi:10.1016/j.ijmm.2012.05.002
50. Smith HW, Green P, Parsell Z (1983) Vero cell toxins in Escherichia coli and related bacteria: transfer by phage and conjugation and toxic action in laboratory animals, chickens and pigs. J Gen Microbiol 129(10):3121–3137
51. Sonnenborn U, Schulze J (2009) The non-pathogenic Escherichia coli strain Nissle 1917—features of a versatile probiotic. Microb Ecol Health Dis 21(3–4):122–158
52. Stein E, Inic-Kanada A, Belij S, Montanaro J, Bintner N, Schlacher S, Mayr UB, Lubitz W, Stojanovic M, Najdenski H (2013) In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases Escherichia coli Nissle 1917 bacterial ghosts. Invest Ophthalmol Vis Sci 54(9):6326–6333. doi:10.1167/iovs.13-12044
53. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA (2007) Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 297(3):151–162. doi:10.1016/j.ijmm.2007.01.008
54. Tzschaschel BD, Guzmán CA, Timmis KN, de Lorenzo V (1996) An Escherichia coli hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin HeB subunit by Salmonella typhimurium aroA. Nat Biotechnol 14:765–769. doi:10.1038/nbt0696-765
55. Whelan RA, Rausch S, Ebner F, Günzel D, Richter JF, Hering NA, Schulzke J-D, Kühl AA, Keles A, Janczyk P (2014) A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation. Mol Ther 22(10):1730–1740. doi:10.1038/mt.2014.125
56. Wood T, Kuhn R, Peretti S (1990) Enhanced plasmid stability through post-segregational killing of plasmid-free cells. Biotechnol Tech 4(1):39–44. doi:10.1007/BF00156608
57. Wu K, Wood TK (1994) Evaluation of the hok/sok killer locus for enhanced plasmid stability. Biotechnol Bioeng 44(8):912–921. doi:10.1002/bit.260440807
58. Yang Y, Yang Y, Ou B, Xia P, Zhou M, Li L, Zhu G (2016) The flagellin hypervariable region is a potential flagella display domain in probiotic Escherichia coli strain Nissle 1917. Arch Microbiol:1–8. doi:10.1007/s00203-016-1219-3
59. Zhang W (2010) Isolation and identification of porcine-originated Escherichia coli Nissle 1917 and its initial assessment as an oral vaccine vector. Dissertation, Yangzhou University
60. Zhang Y, Zhang Y, Xia L, Zhang X, Ding X, Yan F, Wu F (2012) Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4 T1 breast tumors through expression of azurin protein. Appl Environ Microbiol 78(21):7603–7610. doi:10.1128/AEM.01390-12